Table 3.

Clinical, biomarker, ECG, and echocardiographic characteristics of patients with confirmed ATTRwt

Patient	NYHA class	Elevated cardiac troponin	NT‐proBNP, ng/L	eGFR, mL/min/1.73 m2	NAC stage	IVS, mm	PW, mm	LVEF, %	GLS, %	RAS pattern	RASr	Pseudoinfarction	Low voltage	AV conduction disorder	Number of red flags
#1	I	Yes	383	88	I	17	14	56	−13.9	Yes	1.94	No	Yes	No	6
#2	II	Yes	403	>90	I	11	10	53	−16.4	Yes	1.40	No	No	No	3
#3	I	Yes	5303	50	II	13	11	49	−11.5	Yes	2.05	No	No	No	5
#4	I	No	1080	67	I	14	9	40	−11.9	Yes	1.33	No	Yes	No	4
#5	I	Yes	399	>90	I	11	9	58	−18.8	No	1.30	No	No	No	2
#6	II	No	1752	79	I	18	16	76	−15.9	Yes	2.48	Yes	Yes	No	6
#7	I	Yes	284	74	I	11	8	56	−18.6	Yes	1.50	No	No	No	3
#8	II	No	1149	43	II	14	12	63	−16.6	Yes	1.31	No	No	No	3
#9	I	Yes	1157	78	I	19	13	47	−12.2	Yes	2.29	No	No	No	5
#10	I	No	96	>90	I	12	8	58	−19.4	Yes	1.50	No	No	No	3

ATTRwt, wild‐type transthyretin cardiac amyloidosis; AV, atrioventricular; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; IVS, interventricular septum; LVEF, left ventricular ejection fraction; NAC, National Amyloidosis Centre; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PW, posterior wall; RAS, relative apical sparring; RASr, relative apical sparring ratio.